Cytotoxicity of α-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells

International Journal of Radiation Biology

Volumn 72, Issue 1, 1997, Pages 79-90

  Larsen, R H ^a   Vaidyanathan, G ^a   Zalutsky, M R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211;

ALPHA RADIATION; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA CELL; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; RADIOISOTOPE THERAPY;

ALPHA PARTICLES; ANTINEOPLASTIC AGENTS; ASTATINE; DNA, NEOPLASM; GLIOMA; HUMANS; IDOXURIDINE; IODINE RADIOISOTOPES; ISOTOPE LABELING; MELANOMA; TUMOR CELLS, CULTURED;

EID: 0030747554     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/095530097143563     Document Type: Article

References (29)

1. 123I]iodo-2-deoxyuridine in the radiotherapy of an early ascites tumour model. International Journal of Radiation Oncology Biology Physics. 21, 1541-1551.
2. 2 - A preliminary report. Journal of Neuro-Oncology 24, 109-122.
3. BIGNER, S. H., FRIEDMAN, H. S., BIEGEL, J. A., WIKSTRAND, C. J., MARK, J., GEBHARDT, R., ENG, L. F. and BIGNER, D. D., 1986, Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas. Acta Neuropathologia, 72, 86-97.
4. BLOOMER, W. and ADELSTEIN, S. J., 1981, Iodine-125 cytotoxicity: implication for the therapy and estimation of radiation risk. International Journal of Nuclear Medicine and Biology, 8, 171-178.
5. BLOOMER, W. D., MCLAUGHLIN, W. H., WEICHSELBAUM, R. R., HANSON, R. N., ADELSTEIN, S. J. and SEITZ, D. E., 1981, The role of subcellular localization in assessing the cytotoxicity of iodine-125 labeled iododeoxyuridine, iodotamoxifen, and iodoantipyrine. Journal of Radioanalytical Chemistry, 65, 209-221.
6. BRADLEY, E. W., CHAN, P. C. and ADELSTEIN, S. J., 1975, The radiotoxicity of iodine-125 in mammalian cells 1. Effects of the survival curve of radioiodine incorporated into DNA. Radiation Research, 64, 555-563.
7. 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumour resection cavities with subarachnoid communication: phase I trial results. Clinical Cancer Research, 2, 963-972.
8. 210Po alpha particles on survival and preneoplastic transformation of primary rat tracheal epithelial cells irradiated while in suspension or in the intact tissue. Radiation Research, 136, 89-96.
9. HALL, E. J., 1994, Radiobiology for the Radiologist, 4th edn. (Philadelphia: J.B. Lippincott).
10. HOWELL, R. W., 1992, Radiation spectra for Auger-electron emitting radionuclides: Report No. 2 of AAPM nuclear medicine task group No. 6. Medical Physics, 19, 1371-1376.
11. HUMM, J. L. and CHIN, L. M., 1993, A model of cell inactivation by α-particle internal emitters. Radiation Research, 134, 143-150.
12. 125IUdR and other radiolabelled thymidine precursors in resistant tumours. British Journal of Radiology, 64, 45-49.
13. HYMER, W. C. and KUFF, E. L., 1964, Isolation of nuclei from mammalian tissues through the use of Triton X-100. Journal of Histochemistry and Cytochemistry, 12, 359-363.
14. KASSIS, A. I. and ADELSTEIN, S. J., 1982, Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiation Research, 90, 362-373.
15. 125I in mammalian cells. Radiation Research, 111, 305-318.
16. 125IUDR in mammalian cells: Implication of localized energy deposition by Auger processes. Radiation Research, 109, 78-89.
17. 123/125I]iodo-2′-deoxyuridine in rat brain tumours: diagnostic and therapeutic implications in humans. Cancer Research, 50, 5199-5203.
18. KNOL, J. A., WALKER, S. C., ROBERTSON, J. M., YANG, Z., DEREMER, S., STETSON, P. L., ENSMINGER, W. D. and LAWRENCE, T. S., 1995, Incorporation of 5-bomo-2′-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Research, 55, 3687-3691.
19. LARSEN, R. H. and BRULAND, O. S., 1995, Radiolysis of radioimmunoconjugates. Reduction in antigen-binding ability by α-particle radiation. Journal of Labelled Compounds and Radiopharmaceuticals, 36, 1009-1018.
20. 211 At reaction. Applied Radiation and Isotopes, 47, 135-143.
21. 125I]Iodo-2′-deoxyuridine. Radiation Research, 118, 532-544.
22. MARIANI, G., CEI, A., COLLECCHI, P., BARANOWSKA-KORTYLEWICZ, J., VAN DEN ABBEELE, A. D., DI LUCA, L., DI STEFANO, R., VIACAVA, P., FERDEGHINI, E. M., DI SACCO, S., SALVADORI, P. A., BEVILACQUA, G., ADELSTEIN, S. J., MOSCA, F. and KASSIS, A. I., 1993, Tumour targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2-deoxyuridine following intratumoural injection in patients with colorectal cancer. Journal of Nuclear Medicine, 34, 1175-1183.
23. PEREZ, L. A., DOMBKOWSKI, D., EFIRD, J., PFEFFER, F. and SUIT, H. D., 1993, Cell proliferation kinetics in human tumour xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. Cancer Research, 55, 392-398.
24. 125I: cysteamine as a radioprotector against Auger cascades in vivo. Radiation Research, 124, 188-193.
25. 211At decays. Radiochimica Acta, 47, 87-89.
26. 211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Research, 54, 5414-5419.
27. THACKER, J., STRETCH, A. and STEVENS, M. A., 1982, Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. II. Chinese hamster V79 cells. International Journal of Nuclear Medicine and Biology, 9, 167-171.
28. 211At]astato-2′- deoxyuridine, an α-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Research, 56, 1204-1209.
29. WEBER, D. A., ECKERMAN, K. F., DILLMAN, L. T. and RYMAN, J. C., 1989, MIRD: Radionuclide Data and Decay Schemes (New York: Society of Nuclear Medicine).